Gregory M. Lanza, MD, PhD, FACC
Professor of Medicine, Biomedical Engineering, and Biology and Biomedical Sciences
- Phone: 314-454-8635
- Email: greg@cvu.wustl.edu
Additional Titles
- Co-Founder, Chief Scientific Officer and Board Member, Kereos, Inc., St. Louis, MO
- Oliver M. Langenberg Chair, Distinguished Professor of the Science and Practive of Medicine
Related Links
Education
- Bachelor of Arts: Colby College, Waterville, MN (1975)
- Masters of Science: Department of Poultry Science, University of Georgia, Athens, GA (1978)
- Doctor of Philosophy: Department of Poultry Science, University of Georgia, Athens, GA (1981)
- Doctor of Medicine: Northwestern University Medical School, Chicago, IL (1992)
- Residency, Medicine: Department of Medicine, Barnes Hospital, Washington University Medical Center, St. Louis, MO (1994)
- Fellowship, Cardiology: Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO (1999)
Board Certifications
- Cardiovascular Disease
Recognition
- Phi Kappa Phi Honor Society
- Gamma Sigma Delta Agricultural Honor Society
- NCI Unconventional Innovation Program Awards, 2000-2003, 2002-2005, 2003-2006
- NCI Unconventional Innovation Program Awards, 2000-2003, 2002-2005, 2003-2006
- NCI Unconventional Innovation Program Awards, 2000-2003, 2002-2005, 2003-2006
- American Heart Association, Missouri Affiliate – Beginning Grant, 1999-2001
- Barnes-Jewish Hospital Research Foundation Award, 1999-2001
- American College of Cardiology, Searle Career Development Award, 2000
- Bracco Diagnostics Inc./Society for Cardiac Angiography and Interventions Fellowship, 1998
- ACC/Littmann Scholarship Award, 1998
- American Heart Association Fellowship, Missouri Affiliate, 1995-1997
- Bristol-Myers Squibb Fellowship Award, 1997
Clinical Interests
Noninvasive general adult cardiology with clinical emphasis on cardiovascular imaging with echocardiography and magnetic resonance imaging.
Research Interests
Development of novel nanotechnologies for biomedical molecular imaging (Echo, MRI, CT, Photoacoustic tomography, and optical) and targeted drug delivery (chemotherapeutic, thrombolytic, and siRNA/RNAi) in cardiovascular, neurological, inflammatory, and cancer disease. Design and development of novel prodrugs inclusion in lipid-based nanocolloid agents (including chemotherapeutic, peptides, natural products, synthetic biochemical pathway inhibitors).